Bei Akademie registrieren
LNTH, US5165441032

Lantheus Holdings stock heads into results with merger review pending

Published on 10/30/2026 at 00:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lantheus Holdings stock was at EUR 89.75 late on October 29. Investors are focused on quarterly results and the extended FTC review of the Curium merger.

Quartalszahlen treffen auf Fusionsprüfung

  • Investing.com berichtete am 28. Oktober über die Erwartungen für das dritte Quartal und die offenen regulatorischen Fragen.
  • Die FTC verlangte am 21. Oktober zusätzliche Informationen zum geplanten Zusammenschluss mit Curium.
  • PYLARIFY bleibt ein zentraler Beobachtungspunkt, nachdem der Umsatz im zweiten Quartal zurückging.
LNTH, US5165441032, Illustration mit AI erstellt.
LNTH, US5165441032, Illustration mit AI erstellt.

Lantheus Holdings is entering a closely watched phase as investors assess the company’s quarterly performance alongside regulatory uncertainty around its planned combination with Curium. Lang & Schwarz quoted the share at EUR 89.75 on October 29 at 22:59:30 Berlin time. The real-time quote of Lantheus Holdings stock is available separately.

Expectations for the third quarter

In a report published on October 28, Investing.com, citing Reuters, said Wall Street expected third-quarter earnings of USD 1.26 per share and revenue of USD 360.82 million for the period ended September 30. The estimates implied a sequential decline from adjusted second-quarter earnings of USD 1.55 per share and revenue of USD 388.2 million.

The report said analysts were mainly focused on the performance of PYLARIFY, Lantheus’s prostate cancer imaging agent. PYLARIFY sales fell 4.1% in the second quarter to USD 240.4 million, according to the report. DEFINITY provided a counterweight in that quarter, with sales increasing 5.2% to USD 88.3 million.

FTC review adds transaction uncertainty

The Federal Trade Commission issued a second request for information on October 21, extending the antitrust review of the proposed Curium transaction. Lantheus and Curium are still expected to pursue a closing in the first half of 2027, but the additional review prolongs the period in which investors must weigh operating performance against deal execution risk.

Investing.com also reported that Lantheus had suspended full-year guidance in connection with the pending transaction. That makes management commentary on commercial execution, the regulatory timetable and the planned PYLARIFY TruVu conversion especially relevant for the investment case.

Lantheus Holdings at a glance

  • Company: Lantheus Holdings, Inc.
  • ISIN: US5165441032
  • Ticker: LNTH
  • Quote: EUR 89.75, Lang & Schwarz, October 29, 2026, 22:59:30 Berlin time

For broader context, see the current market reports covering the wider market environment.

The US market backdrop remains relevant for Lantheus investors; the S&P 500 theme provides that context.

More news and analyses are available on the Lantheus Holdings stock theme.

Disclaimer...
en | US5165441032 | LNTH | boerse | 70431150 |